AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06244004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET
Study NCT06244004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET
Study NCT06244004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo MDRT
Study NCT06223334 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
Study NCT06322849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation is a potential active element of Project ABC. In psychoeducation, participants learn about the cognitive model of behavior and how they can take action to change their moods.
Study NCT06322849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testimonials and Saying is believing exercises
Description: Testimonials and Saying is believing exercises is a potential active element of Project ABC. In this element, participants learn about how others have taken action to improve their mood and complete one exercise where they give advice to a virtual peer who is stuck in a negative spiral.
Study NCT06322849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Action planning is a potential active element of Project ABC. In this element, participants plan in detail an action they can take to get out of the negative mood spiral.
Study NCT06322849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Participants will be presented with a one-minute breathing exercise.
Study NCT05718947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI (3T, 7T, 9.4T)
Description: All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
Study NCT05933746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Intervention
Description: This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
Study NCT05933746 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-behavioral Sleep Education
Description: 1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
Study NCT06333249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene
Study NCT04309292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic food supplement
Description: Darmocare Pre = trade name Gut microbiome modulator
Study NCT04309292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein supplement
Description: commercially available protein supplementation with high leucine content
Study NCT04309292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: commercially available protein supplementation with high leucine content
Study NCT04309292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltrodextrin (placebo)
Description: Starchy substance
Study NCT04991870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Description: Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
Study NCT04991870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT05696483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX-07010 Active
Description: 25 and 75 mg capsules
Study NCT05696483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OLX-07010 Placebo
Description: 25 and 75 mg capsules
Study NCT04951115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
Study NCT04951115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
Study NCT04951115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
Study NCT04951115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
Study NCT04951115 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: 6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
Study NCT05227456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68mg implant
Description: Implant will be inserted
Study NCT05227456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68mg implant
Description: Implant will be inserted
Study NCT04895254 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic colonoscopy
Description: The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
Study NCT04895254 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic colonoscopy
Description: The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
Study NCT06381804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shotblocker
Description: shotblocker device
Study NCT06381804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palm stimulator
Description: palm stimulator
Study NCT04647370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning
Description: 3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
Study NCT04647370 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: 3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
Study NCT04796714 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Double antiplatelet therapy
Description: One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
Study NCT04796714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: One sachet of aspirin 160 mg per day during 3 months
Study NCT04796714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
Study NCT04796714 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brain MRI
Description: Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
Study NCT04796714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological tests
Description: Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
Study NCT04796714 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neurological tests
Description: Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
Study NCT06107777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Description: Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
Study NCT06107777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study NCT06107777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study NCT05198817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
Description: Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
Study NCT06340022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale
Description: Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.
Study NCT06340022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face Image Scale (FIS) scoring system
Description: Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.
Study NCT06340022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Description: In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.
Study NCT06340022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse rate
Description: Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.
Study NCT06169202 — intervention group
Intervention type: DEVICE
Intervention: fruquintinib
Description: 4 mg orally once daily, D1-14, repeated every 3 weeks.
Study NCT06169202 — intervention group
Intervention type: DRUG
Intervention: Irinotecan
Description: 180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
Study NCT06169202 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
Study NCT05809921 — intervention group
Intervention type: DRUG
Intervention: alteplase
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
Study NCT05809921 — intervention group
Intervention type: DRUG
Intervention: Alteplase + possible complementary IVT with tenecteplase
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
Study NCT06260566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation.
Study NCT04273607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Heparin
Description: The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
Study NCT06019624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Takes!
Description: Receipt of a fresh produce box, nutritional education and support in a 6 month program
Study NCT05749146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study NCT05749146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study NCT06304103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Administer AND017 once per day (QD)
Study NCT06345716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracétamol tramadol
Description: Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
Study NCT06345716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracétamol cafeine
Description: Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
Study NCT06345716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
Study NCT04319367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Medicinal Product
Description: Recombinant human monoclonal antibody (mAb) or placebo
Study NCT04319367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Medicinal Product
Description: Recombinant human monoclonal antibody (mAb) or placebo
Study NCT05095636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: oral Apatinib once everyday
Study NCT05095636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: oral Apatinib once everyday
Study NCT05095636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: intravenous camrelizumab 200mg once every two weeks
Study NCT04870658 — intervention group
Intervention type: PROCEDURE
Intervention: Dental implant treatment
Description: Patients who receive one o more dental implant treatment to restore oral function.
Study NCT05233865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water exercise
Description: Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
Study NCT05233865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Land exercise
Description: Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
Study NCT05685043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perfusion CT
Description: Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients \< 80 years or 55 ml in patients > 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
Study NCT06528288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The erector spinae plane block (ESPB) is a method for injecting local anesthesia to reduce pain related to a surgical procedure. The anesthesia is theorized to spread along the paraspinal fascia and anesthetize a larger area, resulting in patients reporting less pain and using less opioids postoperatively.
Study NCT06528288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Anesthesia
Description: Subcutaneous anesthesia injection involves placement of local anesthesia under the skin around the surgical incision. This is thought to reduce pain from the incision site postoperatively.
Study NCT05789745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human plasma gelsolin
Description: intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
Study NCT05789745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
Study NCT04663321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
Study NCT04663321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose matched placebo capsules BID orally over 4 weeks.
Study NCT04663321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo capsules BID orally over 4 weeks.
Study NCT06088498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Updating Existing Smartphone App
Description: Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 5-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-8 cues, and each cue will be presented for 20-40 seconds (average amount of extinction per day will be about 10 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
Study NCT06088498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Services
Description: Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
Study NCT06088498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Services and Smartphone App
Description: In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
Study NCT04829734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT-sMF
Description: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
Study NCT04829734 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT-sMF
Description: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study NCT06397781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin Cleanser Combination No.1
Description: 1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily.